Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LUMOS PHARMA, INC.(NLNK) · Entity 85102 | Director | May 23, 2018 | May 25, 2018 |
| Replimune Group, Inc.REPL · Entity 4707 | Director | April 01, 2026 | April 08, 2026 |
| WEST PHARMACEUTICAL SERVICES INCWST · Entity 3201 | Director | May 04, 2026 | May 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LUMOS PHARMA, INC.
Report date May 23, 2018 · Filed May 25, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.33 · Expires 2028-05-22 | Direct | 27,777 |
Reported balance
After 2018-05-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-05-23 · Grant · Acquired 27,777 · Balance 27,777 F1: Automatic grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2009 Equity Incentive Plan (the "Plan"). One hundred percent (100%) of the shares shall vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the first Annual Meeting following the date of grant, in each case subject to the Reporting Person's continuous service as of such date. The option expires ten years after the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Automatic grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2009 Equity Incentive Plan (the "Plan"). One hundred percent (100%) of the shares shall vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the first Annual Meeting following the date of grant, in each case subject to the Reporting Person's continuous service as of such date. The option expires ten years after the date of grant.
Replimune Group, Inc.
Report date April 01, 2026 · Filed April 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.61 · Expires 2036-04-01 | Direct | 44,500 |
Reported balance
After 2026-04-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-01 · Grant · Acquired 44,500 · Balance 44,500 F1: The shares underlying this option vest entirely on April 1, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest entirely on April 1, 2027.
WEST PHARMACEUTICAL SERVICES INC
Report date May 04, 2026 · Filed May 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,854.297 |
Reported balance
After 2026-05-04 transaction · row 1
1 source rowRow 1 · 2026-05-04 · Grant · Acquired 791 · Balance 11,854.297 F1: These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ARQULE INC
Report date January 16, 2020 · Filed January 16, 2020
Section 16 reporting ended · disclosed 2020-01-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 1
1 source rowRow 1 · 2020-01-16 · Other · Disposed 1,235,782 · Balance 0 F1: On December 6, 2019, ArQule, Inc. (the "Company") entered into an Agreement and Plan of Merger (as amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Merck Sharpe & Dohme Corp. ("MSD") and Argon Merger Sub, Inc., a wholly-owned subsidiary of MSD ("Merger Sub"), pursuant to which MSD acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 16, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $20.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were cancelled and converted automatically into the right to receive the Offer Price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.16 · Expires 2025-01-20 | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-01-16 · Disposition to issuer · Disposed 242,502 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.79 · Expires 2026-01-19 | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-01-16 · Disposition to issuer · Disposed 120,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.53 · Expires 2027-01-17 | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-01-16 · Disposition to issuer · Disposed 300,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.95 · Expires 2027-04-04 | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-01-16 · Disposition to issuer · Disposed 600,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2028-01-16 | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-01-16 · Disposition to issuer · Disposed 249,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.48 · Expires 2028-05-08 | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-01-16 · Disposition to issuer · Disposed 80,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.48 · Expires 2028-07-23 | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-01-16 · Disposition to issuer · Disposed 150,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.68 · Expires 2029-01-15 | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-01-16 · Disposition to issuer · Disposed 650,850 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.14 · Expires 2020-07-15 | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-01-16 · Disposition to issuer · Disposed 100,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.70 · Expires 2021-01-24 | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2020-01-16 · Disposition to issuer · Disposed 14,925 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.95 · Expires 2022-02-01 | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2020-01-16 · Disposition to issuer · Disposed 7,578 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.51 · Expires 2023-01-14 | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2020-01-16 · Disposition to issuer · Disposed 285,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.57 · Expires 2024-01-22 | Direct | 0 |
Reported balance
After 2020-01-16 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2020-01-16 · Disposition to issuer · Disposed 305,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 6, 2019, ArQule, Inc. (the "Company") entered into an Agreement and Plan of Merger (as amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Merck Sharpe & Dohme Corp. ("MSD") and Argon Merger Sub, Inc., a wholly-owned subsidiary of MSD ("Merger Sub"), pursuant to which MSD acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 16, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $20.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were cancelled and converted automatically into the right to receive the Offer Price.
F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Merus N.V.
Report date December 12, 2025 · Filed December 12, 2025
Section 16 reporting ended · disclosed 2025-12-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.60 · Expires 2035-05-22 | Direct | 0 |
Reported balance
After 2025-12-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-12 · Disposition to issuer · Disposed 13,193 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.73 · Expires 2034-05-07 | Direct | 0 |
Reported balance
After 2025-12-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-12-12 · Disposition to issuer · Disposed 8,844 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.29 · Expires 2033-06-08 | Direct | 0 |
Reported balance
After 2025-12-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-12-12 · Disposition to issuer · Disposed 14,414 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.56 · Expires 2032-05-31 | Direct | 0 |
Reported balance
After 2025-12-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-12-12 · Disposition to issuer · Disposed 16,604 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.15 · Expires 2031-05-28 | Direct | 0 |
Reported balance
After 2025-12-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-12-12 · Disposition to issuer · Disposed 6,120 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.09 · Expires 2030-06-30 | Direct | 0 |
Reported balance
After 2025-12-12 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-12-12 · Disposition to issuer · Disposed 17,262 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time.
F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.
Trillium Therapeutics Inc.
Report date November 17, 2021 · Filed November 19, 2021
Section 16 reporting ended · disclosed 2021-11-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.50 · Expires 2030-11-15 | Direct | 0 |
Reported balance
After 2021-11-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-11-17 · Disposition to issuer · Disposed 67,000 · Balance 0 F1: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 11, 2019 Filed Sep 12, 2019 10:46 UTC | ARQULE INC ARQL · Entity 11927 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $7.95 | $0.00 |
DisclosureSEC source: 0001019695-19-000028 · primary_doc.xml · derivative · entry 2 Pucci Paolo · CIK 0001436861 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,578 Underlying: Common Stock · 5,000 shares Expires 2022-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| September 11, 2019 Filed Sep 12, 2019 10:46 UTC | ARQULE INC ARQL · Entity 11927 | Exercise / conversionCommon Stock | 5,000 | $7.95 | $39,750.00 |
DisclosureSEC source: 0001019695-19-000028 · primary_doc.xml · nonDerivative · entry 1 Pucci Paolo · CIK 0001436861 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 707,417 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the exercise of 5,000 shares that were subject to an option. All exercised shares were retained by Mr. Pucci and no shares were sold. Read SEC document |
| May 07, 2019 Filed May 9, 2019 19:11 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 1,565 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-19-002731 · primarydocument.xml · nonDerivative · entry 1 Pucci Paolo · CIK 0001436861 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,367.184 F1 · price: These shares of restricted stock units will vest in full on the first anniversary of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. F2 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 15:41 UTC | ARQULE INC ARQL · Entity 11927 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001019695-19-000007 · primary_doc.xml · derivative · entry 2 Pucci Paolo · CIK 0001436861 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,502 Underlying: Common Stock · 50,000 shares Expires 2025-01-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 15:41 UTC | ARQULE INC ARQL · Entity 11927 | Exercise / conversionCommon Stock | 50,000 | $1.16 | $58,000.00 |
DisclosureSEC source: 0001019695-19-000007 · primary_doc.xml · nonDerivative · entry 1 Pucci Paolo · CIK 0001436861 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 618,208 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the exercise of 50,000 shares that were subject to an option. All exercised shares were retained by Mr. Pucci and no shares were sold. Read SEC document |
| March 12, 2019 Filed Mar 14, 2019 18:15 UTC | ARQULE INC ARQL · Entity 11927 | GrantEmployee Stock Options · Derivative | 300,000 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001144204-19-014041 · tv516307_4.xml · derivative · entry 1 Pucci Paolo · CIK 0001436861 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2027-04-03 F1 · shares: Represents earned shares with respect to a performance stock option granted on 4/4/2017 that contained performance requirements. The issuer's Board of Directors and Compensation, Nominating and Governance Committee certified as to the performance-goal attainment on 03/12/2019. The shares remain subject to (i) an additional performance requirement tied to the issuer's stock price and (ii) time-based vesting in 12 quarterly installments from 4/4/2017. F1 · derivative.exercise_date: Represents earned shares with respect to a performance stock option granted on 4/4/2017 that contained performance requirements. The issuer's Board of Directors and Compensation, Nominating and Governance Committee certified as to the performance-goal attainment on 03/12/2019. The shares remain subject to (i) an additional performance requirement tied to the issuer's stock price and (ii) time-based vesting in 12 quarterly installments from 4/4/2017. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 14:06 UTC | ARQULE INC ARQL · Entity 11927 | GrantEmployee Stock Options · Derivative | 650,850 | $0.00 Strike: $3.68 | $0.00 |
DisclosureSEC source: 0001019695-19-000001 · primary_doc.xml · derivative · entry 1 Pucci Paolo · CIK 0001436861 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 650,850 Underlying: Common Stock · 650,850 shares Expires 2029-01-15 F1 · derivative.exercise_date: The options vest in four equal annual installments beginning on January 15, 2020. Read SEC document |
| July 23, 2018 Filed Jul 25, 2018 15:55 UTC | ARQULE INC ARQL · Entity 11927 | GrantEmployee Stock Options · Derivative | 150,000 | $0.00 Strike: $5.48 | $0.00 |
DisclosureSEC source: 0001144204-18-039881 · tv499266_4.xml · derivative · entry 1 Pucci Paolo · CIK 0001436861 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2028-07-23 F1 · derivative.exercise_date: The options vest in four equal annual installments beginning on July 23, 2019. Read SEC document |
| June 08, 2018 Filed Jun 11, 2018 16:32 UTC | ARQULE INC ARQL · Entity 11927 | Exercise / conversionStock Option (Right to Buy) · Derivative | 398,736 | $0.00 Strike: $3.95 | $0.00 |
DisclosureSEC source: 0001019695-18-000022 · primary_doc.xml · derivative · entry 5 Pucci Paolo · CIK 0001436861 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 398,736 shares Expires 2018-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 08, 2018 Filed Jun 11, 2018 16:32 UTC | ARQULE INC ARQL · Entity 11927 | Exercise / conversionStock Options (Right to Buy) · Derivative | 101,264 | $0.00 Strike: $3.95 | $0.00 |
DisclosureSEC source: 0001019695-18-000022 · primary_doc.xml · derivative · entry 4 Pucci Paolo · CIK 0001436861 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 101,264 shares Expires 2018-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 08, 2018 Filed Jun 11, 2018 16:32 UTC | ARQULE INC ARQL · Entity 11927 | Tax withholdingCommon Stock | 352,286 | $5.78 | $2,036,213.08 |
DisclosureSEC source: 0001019695-18-000022 · primary_doc.xml · nonDerivative · entry 3 Pucci Paolo · CIK 0001436861 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 568,208 F1 · balance_after: The Reporting Person exercised options that were scheduled to expire on June 9, 2018. As part of the transaction, the Reporting Person paid $250,000 of the aggregate exercise price in cash. The Reporting Person satisfied the balance of the exercise price and applicable tax withholding by electing to have the Company retain shares otherwise issuable upon exercise of the options. No shares were sold into the market as part of this transaction, and the reporting Person continues to hold the net shares realized from the option exercise. Read SEC document |
| June 08, 2018 Filed Jun 11, 2018 16:32 UTC | ARQULE INC ARQL · Entity 11927 | Exercise / conversionCommon Stock | 398,736 | $3.95 | $1,575,007.20 |
DisclosureSEC source: 0001019695-18-000022 · primary_doc.xml · nonDerivative · entry 2 Pucci Paolo · CIK 0001436861 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 920,494 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 08, 2018 Filed Jun 11, 2018 16:32 UTC | ARQULE INC ARQL · Entity 11927 | Exercise / conversionCommon Stock | 101,264 | $3.95 | $399,992.80 |
DisclosureSEC source: 0001019695-18-000022 · primary_doc.xml · nonDerivative · entry 1 Pucci Paolo · CIK 0001436861 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 521,758 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 23, 2018 Filed May 25, 2018 18:00 UTC | LUMOS PHARMA, INC. (NLNK) · Entity 85102 | GrantStock Option (Right to Buy) · Derivative | 27,777 | $0.00 Strike: $5.33 | $0.00 |
DisclosureSEC source: 0001126234-18-000098 · wf-form4_152728559665737.xml · derivative · entry 1 Pucci Paolo · CIK 0001436861 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,777 Underlying: Common Stock · 27,777 shares Expires 2028-05-22 F1 · derivative.exercise_date: Automatic grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2009 Equity Incentive Plan (the "Plan"). One hundred percent (100%) of the shares shall vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the first Annual Meeting following the date of grant, in each case subject to the Reporting Person's continuous service as of such date. The option expires ten years after the date of grant. Read SEC document |
| May 18, 2018 Filed May 18, 2018 12:02 UTC | ARQULE INC ARQL · Entity 11927 | PurchaseCommon Stock | 15,000 | $3.39 | $50,848.50 |
DisclosureSEC source: 0001019695-18-000019 · primary_doc.xml · nonDerivative · entry 1 Pucci Paolo · CIK 0001436861 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 420,494 F1 · price: Reflects the weighted average price as the shares were purchased in multiple transactions. The per share transaction price ranged from $3.3801 to $3.39. The Reporting Person hereby undertakes to provide, upon request, by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 10, 2018 Filed May 11, 2018 11:23 UTC | ARQULE INC ARQL · Entity 11927 | PurchaseCommon Stock | 1,300 | $2.64 | $3,427.06 |
DisclosureSEC source: 0001019695-18-000013 · primary_doc.xml · nonDerivative · entry 1 Pucci Paolo · CIK 0001436861 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405,494 F1 · price: Reflects the weighted average price as the shares were purchased in multiple transactions. The per share transaction price ranged from $2.62 to $2.65. The Reporting Person hereby undertakes to provide, upon request, by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 08, 2018 Filed May 11, 2018 15:56 UTC | ARQULE INC ARQL · Entity 11927 | GrantEmployee Stock Options · Derivative | 80,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001019695-18-000015 · primary_doc.xml · derivative · entry 1 Pucci Paolo · CIK 0001436861 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2028-05-08 F1 · derivative.exercise_date: The options vest in four equal annual installments beginning on May 8, 2019. Read SEC document |
| May 01, 2018 Filed May 3, 2018 21:44 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 1,824 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-002194 · primarydocument.xml · nonDerivative · entry 1 Pucci Paolo · CIK 0001436861 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,802.184 F1 · price: These shares of restricted stock units will vest in full on the first anniversay of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. F2 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
| January 16, 2018 Filed May 10, 2018 14:31 UTC | ARQULE INC ARQL · Entity 11927 | GrantEmployee Stock Options · Derivative | 249,000 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0001019695-18-000009 · primary_doc.xml · derivative · entry 1 Pucci Paolo · CIK 0001436861 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,000 Underlying: Common Stock · 249,000 shares Expires 2028-01-16 F1 · date: Granted on January 16, 2018, subject to stockholder approval received on May 8, 2018. F2 · derivative.exercise_date: The options vest in four equal annual installments beginning on January 16, 2019. Read SEC document |
| September 07, 2017 Filed Sep 8, 2017 10:17 UTC | ARQULE INC ARQL · Entity 11927 | PurchaseCommon Stock | 1,101 | $1.15 | $1,261.09 |
DisclosureSEC source: 0001019695-17-000027 · primary_doc.xml · nonDerivative · entry 1 Pucci Paolo · CIK 0001436861 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 404,194 F1 · price: Reflects the weighted average price as the shares were purchased in multiple transactions. The per share transaction price ranged from $1.14 to $1.15. The Reporting Person hereby undertakes to provide, upon request, by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| September 06, 2017 Filed Sep 7, 2017 10:29 UTC | ARQULE INC ARQL · Entity 11927 | PurchaseCommon Stock | 16,397 | $1.15 | $18,840.15 |
DisclosureSEC source: 0001019695-17-000026 · primary_doc.xml · nonDerivative · entry 1 Pucci Paolo · CIK 0001436861 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 403,093 F1 · price: Reflects the weighted average price as the shares were purchased in multiple transactions. The per share transaction price ranged from $1.13 to $1.15. The Reporting Person hereby undertakes to provide, upon request, by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| September 05, 2017 Filed Sep 6, 2017 11:47 UTC | ARQULE INC ARQL · Entity 11927 | PurchaseCommon Stock | 19,156 | $1.14 | $21,843.59 |
DisclosureSEC source: 0001019695-17-000025 · primary_doc.xml · nonDerivative · entry 1 Pucci Paolo · CIK 0001436861 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 386,696 F1 · price: Reflects the weighted average price as the shares were purchased in multiple transactions. The per share transaction price ranged from $1.13 to $1.15. The Reporting Person hereby undertakes to provide, upon request, by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 29, 2017 Filed Aug 31, 2017 09:52 UTC | ARQULE INC arql · Entity 11927 | PurchaseCommon Stock | 300 | $1.05 | $315.00 |
DisclosureSEC source: 0001019695-17-000024 · primary_doc.xml · nonDerivative · entry 1 Pucci Paolo · CIK 0001436861 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,540 Read SEC document |
| August 28, 2017 Filed Aug 29, 2017 10:10 UTC | ARQULE INC ARQL · Entity 11927 | PurchaseCommon Stock | 2,970 | $1.05 | $3,115.23 |
DisclosureSEC source: 0001019695-17-000023 · primary_doc.xml · nonDerivative · entry 1 Pucci Paolo · CIK 0001436861 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,240 F1 · price: Reflects the weighted average price as the shares were purchased in multiple transactions. The per share transaction price ranged from $1.03 to $1.05. The Reporting Person hereby undertakes to provide, upon request, by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 25, 2017 Filed Aug 28, 2017 11:51 UTC | ARQULE INC ARQL · Entity 11927 | PurchaseCommon Stock | 701 | $1.05 | $735.77 |
DisclosureSEC source: 0001019695-17-000022 · primary_doc.xml · nonDerivative · entry 2 Pucci Paolo · CIK 0001436861 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 364,270 F1 · price: Reflects the weighted average price as the shares were purchased in multiple transactions. The per share transaction price ranged from $1.04 to $1.05. The Reporting Person hereby undertakes to provide, upon request, by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 24, 2017 Filed Aug 28, 2017 11:51 UTC | ARQULE INC ARQL · Entity 11927 | PurchaseCommon Stock | 8,791 | $1.05 | $9,212.09 |
DisclosureSEC source: 0001019695-17-000022 · primary_doc.xml · nonDerivative · entry 1 Pucci Paolo · CIK 0001436861 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,569 F1 · price: Reflects the weighted average price as the shares were purchased in multiple transactions. The per share transaction price ranged from $1.04 to $1.05. The Reporting Person hereby undertakes to provide, upon request, by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 12, 2017 Filed May 16, 2017 17:21 UTC | LUMOS PHARMA, INC. (NLNK) · Entity 85102 | GrantStock Option (Right to Buy) · Derivative | 13,309 | $0.00 Strike: $17.42 | $0.00 |
DisclosureSEC source: 0001126234-17-000055 · wf-form4_149496967848190.xml · derivative · entry 1 Pucci Paolo · CIK 0001436861 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,309 Underlying: Common Stock · 13,309 shares Expires 2027-05-11 F1 · derivative.exercise_date: Automatic grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2009 Equity Incentive Plan (the "Plan"). One hundred percent (100%) of the shares shall vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the first Annual Meeting following the date of grant, in each case subject to the Reporting Person's continuous service as of such date. The option expires ten years after the date of grant. Read SEC document |
| May 02, 2017 Filed May 3, 2017 18:54 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 1,697 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-001685 · primarydocument.xml · nonDerivative · entry 1 Pucci Paolo · CIK 0001436861 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,978.184 F1 · price: These shares of restricted stock units will vest in full after 8 months and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. F2 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
| January 17, 2017 Filed Jan 18, 2017 16:14 UTC | ARQULE INC ARQL · Entity 11927 | GrantEmployee Stock Options · Derivative | 300,000 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001019695-17-000005 · primary_doc.xml · derivative · entry 1 Pucci Paolo · CIK 0001436861 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2027-01-17 F1 · derivative.exercise_date: The options vest in four equal annual installments beginning on January 17, 2018. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 19:07 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantPhantom Stock Unit · Derivative | 56.0308 | $74.12 | $4,153.00 |
DisclosureSEC source: 0001225208-16-039976 · doc4.xml · derivative · entry 1 Pucci Paolo · CIK 0001436861 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56.0308 Underlying: Common Stock · 56.0308 shares Expires not disclosed F1 · derivative.exercise_price: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F1 · derivative.exercise_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F1 · derivative.expiration_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. Read SEC document |
| September 12, 2016 Filed Sep 13, 2016 13:21 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 1,277 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-16-039239 · doc4.xml · nonDerivative · entry 1 Pucci Paolo · CIK 0001436861 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,277 F1 · price: These shares of restricted stock units will vest in full after 8 months and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.